<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="153154">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02047890</url>
  </required_header>
  <id_info>
    <org_study_id>15200</org_study_id>
    <nct_id>NCT02047890</nct_id>
  </id_info>
  <brief_title>Japanese BAY1000394 Monotherapy Phase I Study</brief_title>
  <official_title>An Open-label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Japanese Subjects With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, non-randomized, dose-escalating Phase I study to evaluate the safety,
      tolerability, pharmacokinetics of BAY1000394 given in a 3 days on / 4 days off schedule in
      Japanese subjects with advanced malignancies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with abnormal lab parameters based on descriptive statistics</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of BAY1000394</measure>
    <time_frame>Cycle 1 / Day 1: 0 (pre dose), 0.5, 1, 2, 4, 6, 8, 12 and 24 hours (Day 2, before morning dose). Cycle 1 / Day 10 : 0 (before morning dose), 0.5, 1, 2, 4, 6, 8 and 12 hours (before evening dose)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of the metabolite M1 (BAY107-7746)</measure>
    <time_frame>Cycle 1 / Day 1: 0 (pre dose), 0.5, 1, 2, 4, 6, 8, 12 and 24 hours (Day 2, before morning dose). Cycle 1 / Day 10 : 0 (before morning dose), 0.5, 1, 2, 4, 6, 8 and 12 hours (before evening dose)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>Screening and on Day 21 of even numbered cycle</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>BAY1000394</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 12 subjects will be included: 3 to 6 evaluable subjects for each cohort. The cycle length will be 3 weeks (21 days).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY1000394 (2.5mg)</intervention_name>
    <description>BAY1000934 2.5mg twice a day (bid) in a 3 days on and 4 days off schedule. (Cohort 1)</description>
    <arm_group_label>BAY1000394</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY1000394 (5mg)</intervention_name>
    <description>BAY1000934 5mg twice a day (bid) in a 3 days on and 4 days off schedule. (Cohort 2)</description>
    <arm_group_label>BAY1000394</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese male or female subjects aged â‰¥20 years

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1

          -  Life expectancy of at least 12 weeks

          -  Subjects with advanced, histologically or cytologically confirmed solid tumors, not
             amenable to any standard therapy, have no standard therapy available, or subjects
             must have actively refused any treatment which would be regarded standard, and if in
             the judgment of the investigator, experimental treatment is clinically and ethically
             acceptable

          -  At least 1 tumor lesion evaluable by computer tomography (CT) or scan or magnetic
             resonance imaging (MRI) according to Response Evaluation Criteria in Solid Tumors
             (RECIST) version 1.1

          -  Adequate bone marrow, liver, and renal functions

        Exclusion Criteria:

          -  Anticancer chemotherapy or immunotherapy within 4 weeks of study entry. Mitomycin C
             or nitrosoureas should not be given within 6 weeks of study entry.

          -  Radiotherapy to target lesions within 3 weeks prior to the first dose of study drug.

          -  Use of biological response modifiers, such as granulocyte colony-stimulating factor
             (G-CSF), within 3 weeks prior to the first dose of study drug.

          -  Symptomatic metastatic brain or meningeal tumors.

          -  Investigational drug treatment outside of this study during or within 4 weeks prior
             to study entry.

          -  Blood pressure &lt;100/60 mmHg or pulse &gt;100 BPM
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bayer Clinical Trials Contact</last_name>
    <email>clinical-trials-contact@bayerhealthcare.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 30, 2014</lastchanged_date>
  <firstreceived_date>January 27, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CDK inhibitor</keyword>
  <keyword>BAY1000394</keyword>
  <keyword>Advanced malignancies</keyword>
  <keyword>Japanese</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
